The medical world in 2026 is changing very quietly, but in an important way. Gene editing has shifted from cutting to fine rewriting; cellular reprogramming has passed from the lab to clinical trials; brain stimulation, which was once limited to specialist clinics, is moving into bedrooms; the most prominent trends are increasingly accurate, less invasive, and increasingly integrated into daily life. The following article presents an overview of recent developments in gene editing, aging intervention, obesity treatment, neuropsychiatric treatment, and diagnostic innovation.
Gene Editing: From “Molecular Scissors” to “Molecular Scalpels”
Significant developments in genetic modification in the year 2026 involve a change from destruction to correction. First-generation CRISPR systems eradicate diseased genes by cutting up the DNA, but next-generation base editors and prime editors can precisely alter individual bases without tearing the strands.
At the University of Illinois Urbana-Champaign, a research team used this technology against Huntington’s disease, but in a non-intuitive manner: mutations in the HTT gene are known to be responsible for this neurodegenerative disease. Hence it was thought that the best approach would be to cut off the entire gene; but it is also known that normal huntingtin is essential for the normal functioning of the cells. The team therefore developed a precise method for changing the splice-acceptor site in exon 13 of the HTT gene, to make the cellular machinery “skip” the small exon and thus eliminate the toxic fragments and leave enough of the active huntingtin for the cells to perform their function. After testing more than 140 base editors, they found one that was the most efficient and least prone to off-target effects. When it was injected into the brains of mice, the accumulation of toxic fragments fell significantly, the symptoms improved, and neuronal degeneration was arrested.
This method has the beauty of not repairing the mutation or of switching off the gene but rather changing the way the gene is “read.” The scientists note that in some cases it is not necessary to inactivate the gene or to correct the mutation directly, but merely to correct and regulate the functioning of the protein, which is sufficient to protect the organism from further damage.
From the point of view of the delivery of the gene, it is worth mentioning the progress with the use of a compact nuclease – Un1Cas12f1 – which has multiplex editing capability and is small enough to fit into AAV viral vectors. Among the experiments performed with this system was the precise excision of exon 23 in the Dmd gene, which caused the reversion of dystrophin expression in a mouse model of Duchenne muscular dystrophy. This new technology is of importance, above all, for supplying muscle and the heart, which are difficult to treat with other methods.
The most exciting new discovery in the CRISPR field was the work at the Hong Kong University of Science and Technology. In place of the RNA molecules normally used for targeting and cleavage of the target DNA, the new system reverses the logic, using synthetic DNA as a guide for targeting and cleaving RNA. This new technique is far more chemically stable than RNA, requires no cooling for transport and storage, is far cheaper to produce, can distinguish single-nucleotide differences, and can target not only coding RNA but also microRNA and long non-coding RNA, opening a host of new possibilities for antiviral treatment and diagnostics of infectious diseases.
Aging Intervention: From “Reset” to “Partial Reversal”
The field of genetic medicine is on the brink of a milestone: the technique of cell reprogramming is about to enter its first human clinical trial. This will be a significant step from animal to human.
The logic of this new technology goes back to Shinya Yamanaka’s discovery in 2006 that by introducing four transcription factors, one can turn mature somatic cells into induced pluripotent stem cells; but full reversion to a primitive state can lead to tumors. Partial reversal, which is much less lenient, is to expose the cells to the reprogramming factors for a shorter period of time, which will allow cells to become a little younger, not returning to the primitive state completely. In 2016, the Salk Institute used the cyclic activation and deactivation of Yamanaka factors to extend the life span and improve the regeneration of the body of progeria mice, and in the meantime it has also achieved results in rejuvenating the skin cells, regenerating the muscles and heart, and restoring the memory of old mice.
The first clinical trials in human beings will be performed on the regeneration of damaged optic nerves. The U.S. company Life Biosciences plans to use viral vectors to deliver three reprogramming factors (after excluding c-Myc, closely associated with cancer) into the optic nerve of one eye to treat nerve damage caused by glaucoma or ischemic optic neuropathy. Co-author Noah Davidsohn, Chief Scientific Officer of Rejuvenate Bio, said that the team first thought the mice might not survive at all, but that after a few months they found no visible tumours and the overall state of health actually improved.
Challenges remain. It is very difficult to find the “dose” of reprogramming, because insufficient reprogramming only produces a small effect, and too much can make the cell lose its identity and revert to a totally primitive state, lose its function and even proliferate abnormally. Differential responses among cell types mean a one-size-fits-all approach is not feasible, and the technique has to be adapted to each kind of cell.
Obesity Treatment: Precision Prediction and the Pursuit of “Quality Weight Loss”
GLP-1 agonists such as semaglutide and tirzepatide have revolutionized the treatment of obesity. However, the individual responses to the drugs are very different. A recent association study of GLP-1 therapy, consisting of 27,885 individuals taking the drugs, showed a genetic explanation for these differences.
At the same time, it was found that a missense variant in the GLP1R gene was associated with efficacy: for each effect allele carried, an additional weight loss of approximately 0.76 kg was expected. Meanwhile, variants in GLP1R and GIPR were associated with nausea and vomiting risk, with the GIPR association limited to those using tirzepatide. This means that in the future it may be possible to use genetic tests before prescribing to predict which patients would respond to a drug more strongly and less adversely, thus achieving the goal of precision obesity treatment.
The “side effect of the side effect” of GLP-1 drugs is also being taken seriously. These drugs efficiently deplete the body of fat while also reducing muscle mass. This is particularly disadvantageous in the elderly, as their already scarce muscle reserves are further reduced by any fat-reducing treatment, thereby accelerating the loss of strength, the very thing which most endangers long-term health. Veru Inc. has already completed patient enrollment in its Phase 2b PLATEAU trial, in which over 200 patients over 65 with a BMI of 35 or more were given enobosarm, an oral selective androgen receptor modulator, in combination with semaglutide. This trial is based on the central hypothesis that enobosarm protects muscle and that the preservation of muscle not only preserves physical function but that it also brings about additional weight loss beyond what GLP–based therapies would produce. The preliminary QUALITY trial showed that in 168 patients aged 65 and over, the combination of enobosarm and semaglutide produced significantly less loss of muscle (p=0.002), with even greater fat reduction. At the first interim analysis in the first quarter of 2027, the difference in muscle mass between the two groups at the end of 32 weeks will be revealed—the information that will determine whether this combination therapy can be taken forward to a phase 3 trial.
Neuropsychiatric Treatment: Brain Stimulation Enters the Home
By the end of 2025 and the beginning of 2026 two prescription-grade home neuromodulation devices received FDA premarket approval. It was the most practical step forward in brain stimulation for many decades.
Flow Neuroscience’s FL-100 was licensed in December 2025 as the first device for use at home by patients to stimulate the brain with direct current, as a monotherapy for non-treatment-resistant depression. It consists of a headset which sends a mild current to the left dorsolateral prefrontal area of the brain for 30 minutes every day for 10 weeks. The Empower study revealed remission rates of 44.9% for the FL-100 group compared with 21.8% for the sham group. It also comes with a phone app offering more than 50 behavioral therapy courses, including courses on nutrition, sleep, exercise and meditation.
Then five weeks later Neurolief’s ProlivRx was approved for a different indication: as an add-on treatment for depression resistant to at least one antidepressant. Its mode of action was completely different—it stimulated the occipital and trigeminal nerves and modulated deep brain regions with low-intensity signals “from the periphery into the center.” In the pivotal MOOD trial, the ProlivRx group showed a Hamilton Depression Rating Scale reduction of 8.6 points at 8 weeks versus 6 points for sham, with remission rates of 21.3% versus 6.0%. The use was to be twice a day for 40 minutes per session. The projected launch date was autumn 2026.
One psychiatrist at a medical conference positioned home neuromodulation as a “third-line option,” between medications and clinic-based TMS and ECT. Its main advantage lies in availability: in the United States fewer than 10 percent of private practices or mental health centers offer in-clinic TMS, but devices operated through telemedicine can cover that gap.
Diagnosis and Disease Modeling: Digital Twins and DNA-Guided Detection
NIH scientists have created the first subcellular-resolution digital twin of a human primary cell. The study involved a group of NIH scientists, who used induced pluripotent stem cells to generate retinal pigment epithelium cells as their subject. They collected 3D images of the cells in question—about 1.3 million of them, spread over nearly 4,000 confocal microscopic fields—and trained an artificial intelligence to identify their nuclei, organelles and cellular components.
This atlas showed the predictable path by which healthy RPE cells go from a non-polarized state to polarized states. In age-related macular degeneration, the loss of apical-basal polarity in RPE cells is a core pathological event. The digital twin thus represents a reference point for the study of the changes that occur in this organization in disease, and for the screening of therapeutic agents to restore polarity with unprecedented precision.
The DNA-guided CRISPR system from the Hong Kong University of Science and Technology is particularly useful in diagnostics. The ability to detect single-nucleotide differences makes it possible to distinguish viral variants. The technology is based on SLEUTH, which uses the stability of DNA as a guide and the low cost of synthesis (synthetic DNA is much cheaper than RNA) to solve the problem of rapid detection of infection in resource-poor settings.
Conclusion
They all have one thing in common: the scale of intervention is moving from broad-brush to precise. In 2026, gene editing is no longer crude cutting, but fine splicing regulation; anti-aging is no longer wholesale resetting but controlled partial reversal; weight loss is no longer just about the number on the scale, but about an individual program based on one’s genetic background and the pursuit of “quality weight loss”; neural stimulation is no longer confined to special clinics, but is entering the home; disease modeling is no longer based solely on animal models, but on digital twins.
These shifts are the expression of the deeper trend in medicine, which is learning to live with biological complexity instead of trying to master it with a single tool. The “sense of proportion” in partial reprogramming, the “non-cutting” strategy of base editing, and the “third-line positioning” of home neuromodulation—these modest, regulated designs, rather than radical technological breakthroughs, might better represent the medical temperament of the times.
KEN ROBERTS